Cellectis SA (CLLS)
1.85
-0.01
(-0.54%)
USD |
NASDAQ |
Nov 22, 12:31
Cellectis Revenue (Quarterly): 16.20M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 16.20M |
| June 30, 2024 | 8.061M |
| March 31, 2024 | 4.528M |
| December 31, 2023 | 0.283M |
| September 30, 2023 | 0.155M |
| June 30, 2023 | 0.179M |
| March 31, 2023 | 0.138M |
| December 31, 2022 | 16.02M |
| September 30, 2022 | 0.176M |
| June 30, 2022 | 1.306M |
| March 31, 2022 | 1.666M |
| December 31, 2021 | -14.74M |
| September 30, 2021 | 8.311M |
| June 30, 2021 | 11.18M |
| March 31, 2021 | 25.60M |
| December 31, 2020 | -8.98M |
| September 30, 2020 | 6.179M |
| June 30, 2020 | 2.90M |
| March 31, 2020 | 50.13M |
| December 31, 2019 | 4.434M |
| Date | Value |
|---|---|
| September 30, 2019 | 8.488M |
| June 30, 2019 | 1.152M |
| March 31, 2019 | 1.036M |
| December 31, 2018 | 0.869M |
| September 30, 2018 | 0.905M |
| June 30, 2018 | 5.049M |
| March 31, 2018 | 6.04M |
| December 31, 2017 | 5.772M |
| September 30, 2017 | 6.122M |
| June 30, 2017 | 6.494M |
| March 31, 2017 | 6.737M |
| December 31, 2016 | 8.106M |
| September 30, 2016 | 11.26M |
| June 30, 2016 | 17.60M |
| March 31, 2016 | 7.908M |
| December 31, 2015 | 29.58M |
| September 30, 2015 | 8.550M |
| June 30, 2015 | 8.219M |
| March 31, 2015 | 9.127M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-14.74M
Minimum
Dec 2021
50.13M
Maximum
Mar 2020
6.686M
Average
3.667M
Median
Revenue (Quarterly) Benchmarks
| Edap TMS SA | 14.41M |
| DBV Technologies SA | -- |
| Genfit SA | 15.36M |
| Adaptimmune Therapeutics PLC | 40.90M |
| Akari Therapeutics PLC | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -23.06M |
| Total Expenses (Quarterly) | 26.97M |
| EPS Diluted (Quarterly) | -0.23 |
| Enterprise Value | -28.39M |
| Profit Margin (Quarterly) | -142.3% |
| Earnings Yield | -72.43% |
| Normalized Earnings Yield | -51.30 |